MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Cytokinetics, Incorporated Market Cap 2011-2026 | CYTK
As of January 26, 2026 Cytokinetics, Incorporated has a market cap of $ 7.15 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Cytokinetics, Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.29 M | 7.11 M | 3.88 M | 3.5 M | 1.34 M | 740 M | 378 M | 455 M | 401 M | 299 M | 253 M | 219 M | 120 M | 73.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 740 M | 1.34 M | 211 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K |  USA |
 |
Adagene
ADAG
|
87.8 M | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 0.97 | 0.81 % | $ 5.29 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.62 | 1.91 % | $ 8.71 B |  Australia |
 |
Biogen
BIIB
|
19.3 B | $ 172.5 | 0.53 % | $ 25.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 117.41 | 1.23 % | $ 27.2 B | Germany |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 12.1 | -5.47 % | $ 797 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Cellectis S.A.
CLLS
|
203 M | $ 4.16 | -5.88 % | $ 116 M | France |
 |
BioXcel Therapeutics
BTAI
|
5.37 M | $ 1.79 | -1.92 % | $ 4.54 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.98 | -3.75 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 231.73 | -1.55 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.72 | -0.31 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 67.09 | 0.06 % | $ 8.97 B | USA |
 |
Compugen Ltd.
CGEN
|
148 M | $ 2.05 | -2.15 % | $ 184 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 4.41 | -1.34 % | $ 9.6 B | Israel |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 26.4 | 1.85 % | $ 1.28 B | USA |
 |
Coherus BioSciences
CHRS
|
209 M | $ 2.27 | 10.19 % | $ 214 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
1.83 B | $ 13.54 | 1.12 % | $ 4.18 B | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 26.48 | 2.16 % | $ 1.71 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.73 | 1.11 % | $ 17.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 94.12 | 1.25 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |